Expedition Therapeutics 在从复星制药获得其主要资产的授权后不久,10月9日宣布完成1.65亿美元A轮融资,由Sofinnova Investments和Novo Holdings共同领投,用于加速慢性阻塞性肺病(COPD)项目的全球开发,并计划扩展至其他中性粒细胞驱动的炎症疾病。该轮融资其他参投方包括Forbion、Dawn Biopharma和Sanofi ...
Source LinkExpedition Therapeutics 在从复星制药获得其主要资产的授权后不久,10月9日宣布完成1.65亿美元A轮融资,由Sofinnova Investments和Novo Holdings共同领投,用于加速慢性阻塞性肺病(COPD)项目的全球开发,并计划扩展至其他中性粒细胞驱动的炎症疾病。该轮融资其他参投方包括Forbion、Dawn Biopharma和Sanofi ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.